@article{23206,
  keywords = {Female, Humans, Aged, Double-Blind Method, Male, Treatment Outcome, Middle Aged, Risk Factors, Renal Dialysis, Acute Kidney Injury, Creatinine, Administration, Oral, Infusions, Intravenous, Fluid Therapy, Renal Insufficiency, Chronic, Sodium Chloride, Acetylcysteine, Angiography, Contrast Media, Sodium Bicarbonate},
  author = {Gallagher M. and Cass Alan and Parikh Chirag and Weisbord Steven and Jneid Hani and Garcia Santiago and Thwin Soe-Soe and Conner Todd and Chertow Glenn and Bhatt Deepak and Shunk Kendrick and McFalls Edward and Brophy Mary and Ferguson Ryan and Wu Hongsheng and Androsenko Maria and Myles John and Kaufman James and Palevsky Paul and PRESERVE Trial Group},
  title = {Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine.},
  abstract = {<p><b>BACKGROUND: </b>Intravenous sodium bicarbonate and oral acetylcysteine are widely used to prevent acute kidney injury and associated adverse outcomes after angiography without definitive evidence of their efficacy.</p><p><b>METHODS: </b>Using a 2-by-2 factorial design, we randomly assigned 5177 patients at high risk for renal complications who were scheduled for angiography to receive intravenous 1.26% sodium bicarbonate or intravenous 0.9% sodium chloride and 5 days of oral acetylcysteine or oral placebo; of these patients, 4993 were included in the modified intention-to-treat analysis. The primary end point was a composite of death, the need for dialysis, or a persistent increase of at least 50% from baseline in the serum creatinine level at 90 days. Contrast-associated acute kidney injury was a secondary end point.</p><p><b>RESULTS: </b>The sponsor stopped the trial after a prespecified interim analysis. There was no interaction between sodium bicarbonate and acetylcysteine with respect to the primary end point (P=0.33). The primary end point occurred in 110 of 2511 patients (4.4%) in the sodium bicarbonate group as compared with 116 of 2482 (4.7%) in the sodium chloride group (odds ratio, 0.93; 95% confidence interval [CI], 0.72 to 1.22; P=0.62) and in 114 of 2495 patients (4.6%) in the acetylcysteine group as compared with 112 of 2498 (4.5%) in the placebo group (odds ratio, 1.02; 95% CI, 0.78 to 1.33; P=0.88). There were no significant between-group differences in the rates of contrast-associated acute kidney injury.</p><p><b>CONCLUSIONS: </b>Among patients at high risk for renal complications who were undergoing angiography, there was no benefit of intravenous sodium bicarbonate over intravenous sodium chloride or of oral acetylcysteine over placebo for the prevention of death, need for dialysis, or persistent decline in kidney function at 90 days or for the prevention of contrast-associated acute kidney injury. (Funded by the U.S. Department of Veterans Affairs Office of Research and Development and the National Health and Medical Research Council of Australia; PRESERVE ClinicalTrials.gov number, NCT01467466 .).</p>},
  year = {2018},
  journal = {N Engl J Med},
  volume = {378},
  pages = {603-614},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1710933},
  language = {eng},
}